Alcon Reports Higher H1 Net Income and Sales with Strong Global Presence

Alcon Inc., the global leader in ophthalmic care products, has reported higher H1 net income and sales. Net sales break down into ophthalmic surgical products and equipment (56.1%), and vision care products (43.9%), with a global presence across 17 production sites worldwide.

Alcon Inc., the global leader in ophthalmic care products, has reported a robust performance for the first half of 2025, with higher net income and sales. The company's net sales reached $5.0 billion, up 2% compared to the first half of 2024, excluding unfavorable currency impacts of 1% on a constant currency basis [1].

The company's net sales break down into ophthalmic surgical products and equipment (56.1%) and vision care products (43.9%). Surgical products, which include implantables, consumables, and equipment/other, generated $2.8 billion in sales, a 1% increase on a reported basis and a 1% increase on a constant currency basis. Vision care products, which include contact lenses and ocular health products, generated $2.2 billion in sales, a 4% increase on a reported basis and a 5% increase on a constant currency basis [1].

Alcon's operating income for the first half of 2025 was $715 million, up 4% compared to the prior year period, and operating margin increased by 0.3 percentage points to 13.9%. Core operating income was $491 million, in line with the prior year period on a reported basis [1].

The company also announced the launch of Tryptyr, a first-in-class treatment for dry eye disease, in the US, and the acquisition of STAAR Surgical, expanding Alcon's presence in myopia correction. The acquisition of STAAR Surgical, which includes its market-leading Implantable Collamer Lens, EVO, is expected to position Alcon to offer a full spectrum of treatments for myopia [1].

Alcon's strong financial performance and strategic initiatives position the company well for continued growth and innovation in the ophthalmic care market.

References:
[1] https://www.morningstar.com/news/business-wire/20250816780420/alcon-reports-second-quarter-2025-results-launched-tryptyr-and-announced-acquisition-of-staar-surgical